| Wednesday, Jan. 26, 2022  Caption: This colorized scanning electron micrograph shows chronically infected and partially lysed cells (brown) infected with a variant strain of SARS-CoV-2 virus particles (purple), isolated from a patient sample. SARS-CoV-2 is the virus that causes COVID-19. A drug that blocks danger signals that can lead to harmful inflammation could help reduce COVID-19 lung damage, a new study from NIAID scientists and colleagues has found. The scientists think their findings in mice, published online in JCI Insights, are important enough to pursue further studies of the drug, FPS-ZM1, to determine dosing and timing strategies for possible human clinical trials. FPS-ZM1 is an immune modulatory therapeutic – the drug is designed to prevent a specific immune system response from occurring. The investigational therapy has been evaluated in preclinical studies to treat conditions such as diabetes, lung injury and stroke. Therapeutic treatment with FPS-ZM1 during the study improved survival in mice infected with SARS-CoV-2, the virus that causes COVID-19. Further, FPS-ZM1 specifically reduced damage to the lung vasculature, an important system for circulating blood through the lungs that becomes damaged during SARS-CoV-2 infection.  | 
No comments:
Post a Comment